News Business Personalized Vaccine Shows Early Promise in Metastatic Colorectal Cancer
0
Cancer vaccine

Published :

Personalized Vaccine Shows Early Promise in Metastatic Colorectal Cancer

By Jordyn Sava | April 2, 2024

Colorectal cancer image

Introduction

A groundbreaking phase 2/3 study has unveiled promising results for a personalized neoantigen cancer vaccine known as GRANITE (GRT-C901/GRT-R902). This innovative vaccine, when combined with standard therapy, demonstrates early signs of efficacy and safety in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC).

Study Details

The study enrolled 104 patients in a 1:1 fashion, with 67 patients included in the treated analysis. Among them, 39 received the GRANITE vaccine, while 28 were in the control arm. Notably, 36 patients left the study due to early progressive disease or withdrawal of consent.

Promising Results

GRANITE exhibited positive early progression-free survival (PFS) and long-term circulating tumor DNA (ctDNA) responses compared to the control group receiving fluoropyrimidine/bevacizumab (Avastin) alone. The PFS difference was particularly pronounced in a high-risk subgroup, suggesting potential clinical benefit.

Immune Response Activation

GRANITE's ability to induce a significant immune response in a previously considered "immunologically cold" disease is a breakthrough. These preliminary findings provide a strong rationale for a confirmatory phase 3 trial.

ctDNA Insights

ctDNA responses aligned with the positive PFS trend. In the high-risk group, ctDNA shifted from high to low levels in patients treated with GRANITE, indicating disease control. Additionally, sustained ctDNA negativity was observed in the low-risk group.

Conclusion

While early, these promising results suggest that GRANITE has the potential to deliver clinically meaningful benefit in MSS-CRC and other cold tumors. Expanding the scope of immunotherapy to a broader spectrum of cancer patients remains a critical goal in oncology.

  • Reactions

    0
    0
    0
    0
    0
    0

    Your email address will not be published. Required fields are marked *